Cellomics, Inc. Names Vice President and Chief Financial Officer.

PITTSBURGH--(BW HealthWire)--Nov. 11, 1998--Cellomics, Inc. announced today the appointment of L. Robert Johnston Jr., as Vice President and Chief Financial Officer. Mr. Johnston joins Cellomics after four years at Oncormed, Inc., a genomics services company, where he served as Senior Vice President and CFO. Mr. Johnston previously held various positions in the Finance/Treasury department at American Mobile Satellite Corporation, a nationwide provider of wireless communications services.

"Cellomics, Inc. is very fortunate to have attracted someone with the experience and expertise of Bob Johnston," stated D. Lansing Taylor, Cellomics' President & CEO. "Bob's experience in the biotechnology and telecommunications industries will serve us well in our drug discovery platform and bioinformatics business."

Mr. Johnston received his MBA degree from The Colgate Darden Graduate School of Business Administration at the University of Virginia where he also received his Bachelor's degree.

Cellomics, Inc. is a privately held corporation, founded in October 1996. Cellomics, Inc.'s mission is to improve the efficiency of the drug discovery process by delivering a cell-based screening platform that automates target validation, primary screening and lead optimization using fluorescence-based assays. Today, the Company's integrated platform consists of proprietary fluorescence reagents and assays, a novel, proprietary, cell-based High Content Screening (HCS) system, data management and bioinformatics software. Unlike traditional methods in the drug discovery process, the Company's platform provides deep biological information (time, space, and activity) about a drug candidate's physiological impact on specific cellular targets within living cells. This approach provides significant insight into the potential efficacy and toxicity of a drug candidate on cells before initiating animal testing and human clinical trials, thereby saving substantial time and expense. In addition, the Company co-markets the Carl Zeiss Ultra High Throughput Screening (UHTS) system that can be combined directly with the Cellomics, Inc. HCS system through an exclusive, world-wide alliance with Carl Zeiss Jena, GmbH, the world's leader in optical instrumentation and automation. Cellomics, Inc. will develop new reagents, complete screens, data management tools and bioinformatics as part of the alliance. Combining UHTS with HCS is a new paradigm in drug discovery. The Company is also developing the next generation, cell-based screening platform, the CellChip(TM) System, and the Cellomics(TM) Database to further optimize the drug discovery process.